Berinert denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BlueCross BlueShield May Deny Berinert as "Not FDA-Approved"

Berinert is an FDA-approved plasma-derived C1 esterase inhibitor (C1-INH) concentrate for the treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents. A "not FDA-approved" denial for Berinert from BCBS is almost always the result of a documentation or claims-processing issue rather than a genuine regulatory question. Common triggers include: the diagnosis code on the claim does not clearly correspond to an approved indication; the prescriber's order or letter describes the clinical use in language that reads as off-label; the claim was submitted for a route of administration or a patient age group that differs from what was authorized; or BCBS's claims system flagged the drug code in error. Because FDA approval of Berinert for HAE is unambiguous, this denial type is among the most straightforward to overturn with correct documentation.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you are entitled to a full-and-fair internal appeal and, if denied, independent external review through an accredited IRO. File the external-review request within four months of the final adverse determination. Given the potentially life-threatening nature of severe HAE attacks, expedited review (72-hour decision) is available and should be used when there is clinical urgency.

## The Appeal Process

1. Request the denial letter and identify the exact language BCBS used to characterize the "not FDA-approved" basis. 2. Obtain the current FDA-approved prescribing information for Berinert from the FDA website. 3. Confirm that the diagnosis code and prescriber order language align precisely with the approved indication. 4. File a Level 1 internal appeal with the FDA label and corrected documentation. 5. If upheld, proceed to external IRO review — independent reviewers are required to apply objective evidence standards, not internal plan policy.

## Documentation to Gather

• FDA prescribing label: Download the current Berinert prescribing information from FDA.gov and highlight the approved indication, patient population, and route of administration.
• Diagnosis documentation: Lab or genetic confirmation of hereditary angioedema (C1-INH deficiency or dysfunction) that maps directly to the FDA-approved indication.
• Prescriber attestation: A brief letter from the treating HAE specialist confirming the specific FDA-approved indication under which Berinert was prescribed, using language that mirrors the label's indication statement.
• Claims code review: Ask the prescribing office and pharmacy/infusion center to confirm that all relevant diagnosis and drug codes were submitted correctly and match the authorized indication.
• BCBS policy review: Request the BCBS Medical Policy for Berinert and identify whether the policy's own criteria list FDA approval for the relevant indication — use that language in your response.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Evidence | |---|---| | BCBS claim that use is not FDA-approved | Current FDA label — approved indication, patient population, route | | Diagnosis code mismatch (if applicable) | Corrected claim with matching diagnosis code + lab/genetic confirmation | | Off-label language in prescriber order (if applicable) | Corrected prescriber letter using label indication language | | Any BCBS policy criterion | Policy text matched to chart evidence |

Presenting the FDA label alongside a corrected, label-aligned prescriber letter typically resolves a "not FDA-approved" denial at the Level 1 internal appeal stage.